Biotech company VaLogic has acquired a 75,400-square-foot building in Frederick to create a suburban tech center near Interstate 270. The company bought a vacant commercial building at 7495 New Horizon Way for $7.7 million and soon will begin to gut and redo the interior to create the new office and lab space to lease to several smaller companies. VaLogic for years has consulted on engineering and compliance issues for life science and bioscience companies. It is one of dozens of existing bioscience companies in the county, which is considered a suburb of both Baltimore and Washington, D.C. because of its location off Interstates 70 and 270.
The biotechnology and pharmaceuticals industry continues to heat up in Frederick, with startups launching and raising significant funding, and larger companies expanding beyond hubs like Gaithersburg and Rockville. And these companies all need lab space to grow. Co-founders Doug Bane and Luis Rugeles are aiming to fill that need with a newly renovated 22,000-square-foot building in Frederick, specially outfitted to serve that growing pool of biotechs. The space, called I-270 Innovation Labs, is stationed in the Westview Business Park at 5107 Pegasus Court and provides researcher-grade facilities for growing companies in need of affordable lab space. Bane and Rugeles said the concept for the space came from a group of local investors — including themselves, but the rest of whom they did not name — who recognized the need for additional biotech-focused real estate assets. The space is designed to be flexible, to accommodate members that may need to rent space only temporarily or for longer periods.
Matan Companies has broken ground on the third of its six Progress Labs developments along the I-270 corridor, Progress Labs at Riverside I in Frederick, Maryland. The speculative project, slated to deliver in the Fall of 2022, will total 215,000 square feet comprised of a single story 118,000 square foot biomanufacturing building, along with a three story 96,000 square foot support building to accommodate additional manufacturing, lab, quality control, administration, and support space. The facility will bring in excess of 1,000 new life science jobs to Frederick.
Beckham Gumbin Ventures (BGV), a commercial real estate investor and developer, is beginning construction on brand new R&D laboratory spec suites and amenities at Ballenger Bio (321 Ballenger Center Drive) in Frederick, Maryland. Ballenger Bio will offer several 3,000 to 7,000 SF R&D laboratory spec suites, with the ability to combine up to 37,000 SF of contiguous space on a single floor. Building such spec labs will allow for growing biotech companies to focus on their business as opposed to construction costs and timelines.
Virginia Beach is seeking to build a bio cluster in the heart of everything Virginia Beach has to offer. The cluster reached an important milestone, recently opening a brand new accelerator lab constructed and managed by BioHealth Capital Region (BHCR) stalwart Facility Logix. VABeachBio and its partners see this new lab as a sign of great things to come.
Matan Companies announces today leasing has begun at Progress Labs at Riverside I in Frederick, Maryland. Receiving its site plan approval on March 9, the 215,000 square feet of biomanufacturing-ready space will include a 96,000 square foot existing building as well as a 119,000 square foot expansion building, which is slated to break ground in May 2021 and is expected to be fully complete by Spring 2022.
The Tumor-Infiltrating Lymphocytes (TIL) Cell Processing Modular Facility is the first large-scale, fully prefabricated and modular multi-module cGMP manufacturing facility of its kind ever built in the United States. The National Cancer Institute (NCI) will utilize the facility to deliver cutting-edge cancer treatment.
Matan Companies announced today the signing of a long-term lease with Ellume, an Australian-based company that develops diagnostic solutions for infectious diseases. The Frederick facility, totaling over 180,000 square feet in two full buildings at Progress Labs at Center 85, will be Ellume’s first in the United States and will produce diagnostic tests for infectious diseases, including at-home rapid tests for COVID-19.